Huberman LabFemale Hormone Health, Fertility & Vitality | Dr. Natalie Crawford
CHAPTERS
- 0:00 – 4:05
Intro, Guest Background, and Episode Scope
Huberman introduces the podcast and Dr. Natalie Crawford, outlining her training in OB/GYN, reproductive endocrinology, infertility, and nutrition. They preview a wide-ranging discussion from fetal egg development to menopause, including puberty timing, birth control, egg freezing, IVF, and lifestyle factors.
- •Crawford specializes in fertility and female hormone health, sees patients daily, and does extensive public education.
- •Episode will cover in utero egg development through menopause, plus male fertility components.
- •Goal is to provide clear, actionable, science-based tools for fertility and hormone health.
- 4:05 – 17:10
Fetal Egg Development, Puberty Timing, and Early Puberty Concerns
Crawford explains that female fetuses reach peak egg count at ~20 weeks gestation and lose eggs continuously thereafter. They discuss the stages of female puberty, the shift toward earlier menarche, and what puberty timing does and does not predict about reproductive lifespan.
- •Peak 6–7 million oocytes at ~20 weeks in utero; reduced by more than half at birth; steady attrition thereafter.
- •Puberty sequence: adrenal/sexual hair (adrenarche), breast budding (thelarche), then menarche; breast development ~2 years before first period.
- •Average menarche has shifted from ~13–15 down to ~10–13 years, likely influenced by endocrine disruptors, nutrition, and obesity.
- •Earlier menarche is associated with earlier growth plate closure and shorter adult height, but does NOT shorten total reproductive lifespan or cause earlier menopause.
- 17:10 – 38:20
Endocrine Disruptors, Scents, and Early Sexual Development
They differentiate between true central puberty and pseudo-puberty driven by exogenous estrogens from products like lavender, tea tree oil, or certain fragrances. Crawford emphasizes chronic exposure over one-off contact and urges unscented, low-toxin products for children.
- •Phytoestrogens and endocrine-disrupting chemicals (e.g., lavender, tea tree, some fragrances) can cause breast budding or secondary sex characteristics without turning on the brain’s puberty axis.
- •Pediatric endocrinologists distinguish central precocious puberty from peripheral estrogen exposure using bone age and hormone testing.
- •Many exposures during the 1980s–90s pregnancy cohorts (plastics, processed foods, toxins) likely programmed today’s women for issues like low ovarian reserve, PCOS, or endometriosis.
- 38:20 – 1:00:00
Menstrual Cycle Physiology and Why Cycle Length Matters
Crawford gives a structured explanation of the menstrual cycle—follicular vs luteal phases, hormonal changes, and how these relate to mood and fertility. She stresses that cycle regularity, not an exact 28-day length, is the key health indicator and highlights shortening cycles as a red flag for diminished ovarian reserve.
- •Day 1 of menses is cycle day 1; bleeding marks shedding of the endometrial lining.
- •Follicular phase: FSH stimulates follicles to grow and produce estrogen; women often feel best cognitively and emotionally in this high-estrogen phase.
- •LH surge after sustained high estradiol triggers ovulation; corpus luteum forms and produces progesterone (luteal phase).
- •Luteal phase length is usually fixed at ~12–14 days; cycle length variation mostly occurs in the follicular phase.
- •Predictable cycles even at 24 or 33 days are fine; large variability month-to-month is not.
- •Sudden cycle shortening in a woman who previously had longer cycles can signal declining ovarian reserve.
- 1:00:00 – 1:12:10
Birth Control Pills and Their True Effects on Fertility
They unpack what combined oral contraceptives actually do: suppress ovulation, thin endometrial lining, and distort some fertility tests—but they do not shrink ovarian reserve or cause future infertility. Crawford discusses how the pill affects AMH testing and how long-term use may sometimes improve fertility in conditions like endometriosis.
- •Combined pills use ethinyl estradiol plus a progestin; both differ structurally from natural estradiol and progesterone.
- •Pills suppress FSH/LH, preventing ovulation, but eggs still leave the vault and are lost each month.
- •AMH can be suppressed by ~30% on pill users; low AMH on pills should be rechecked after several months off.
- •Long-term pill use can protect against endometriosis flares and unopposed estrogen, potentially supporting better fertility later for some women.
- •Common concerns that the pill 'uses up eggs' or causes early menopause are incorrect.
- 1:12:10 – 1:18:20
Male Testosterone, Spermatogenesis, and Pill vs. Testosterone Suppression
They contrast male and female gamete biology: females are born with all their eggs, whereas men continuously produce new sperm. Exogenous testosterone in men shuts down FSH/LH and thus sperm production, but pill use in women does not affect long-term egg loss.
- •Spermatogenesis takes ~72 days plus ~18 days of transport; continuous and FSH/LH-dependent.
- •Exogenous testosterone tells the brain 'we have enough' and suppresses FSH/LH, halting sperm production.
- •Long-term testosterone can lead to incomplete or absent recovery of sperm production in ~25% of men.
- •Women’s egg attrition is fixed and independent of pills; pills only alter ovulation and hormone milieu.
- 1:18:20 – 1:33:20
Cannabis, Cigarettes, Vaping, and Alcohol on Egg and Sperm Quality
Crawford outlines the evidence that smoking cigarettes, vaping, and cannabis use are detrimental to both egg and sperm quantity/quality and raise miscarriage rates. Alcohol’s impact is dose-dependent and primarily through chronic inflammation; zero alcohol is advised in pregnancy.
- •Smoking cigarettes reduces egg number, lowers AMH, and increases aneuploidy and miscarriage; it also advances menopause.
- •Vaping contains toxic chemicals associated with lower IVF success; data are emerging but concerning.
- •Cannabis reduces sperm count, motility, morphology, and increases DNA fragmentation and miscarriage risk even with normal semen analyses.
- •Alcohol is a liver-processed toxin that drives inflammation; heavy or chronic use impairs fertility and increases miscarriage risk.
- •No safe alcohol level in pregnancy regarding fetal alcohol spectrum disorders.
- 1:33:20 – 1:42:30
IUDs, Depo-Provera, and Other Hormonal Contraception Nuances
They differentiate copper and hormonal IUDs, as well as Depo-Provera and the vaginal ring, detailing how each works, how they affect ovulation, and specific fertility-relevant caveats like time to return of cycles after removal.
- •Copper IUD: non-hormonal, creates a toxic inflammatory environment for sperm and implantation; ovulation continues, periods can be heavier.
- •Progestin IUDs (Mirena etc.): primarily thin endometrial lining; about half of users still ovulate; amenorrhea usually reflects a very thin lining.
- •Amenorrheic IUD users should remove device 3–6 months before trying to conceive to allow lining to regrow.
- •Depo-Provera: high-dose progestin that reliably blocks ovulation for ≥3 months; suppression can last up to 18 months.
- •Crawford suggests discontinuing Depo 1.5–2 years before planned pregnancy.
- 1:42:30 – 2:16:40
Clotting Risk, Factor V Leiden, and Pill Safety
The discussion moves to blood clot risk with estrogen-containing pills and inherited thrombophilias like Factor V Leiden. Crawford explains current guidelines, practical screening strategies, and when to insist on additional testing.
- •Pill-associated clot risk stems from first-pass liver metabolism and increased clotting factors.
- •Routine screening for clotting mutations is not standard before prescribing pills.
- •Anyone with personal or family history of deep vein thrombosis (DVT) or pulmonary embolism (PE) should be tested for inherited thrombophilias (e.g., Factor V Leiden) before using estrogen.
- •If a clot occurs on pills, a full thrombophilia workup is done and estrogen-containing methods are discontinued; non-estrogen contraception remains possible.
- 2:16:40 – 2:35:00
AMH, Antral Follicle Counts, and Why Screening Matters Despite Guidelines
They delve deeply into ovarian reserve testing: AMH and antral follicle count by ultrasound. ACOG’s official stance against routine AMH screening is contrasted with Crawford’s strong advocacy for proactive testing and informed decision-making about egg freezing and timing of family-building.
- •Antral follicle count (AFC) represents the number of small follicles visible on ultrasound; it approximates how many eggs leave the vault that month.
- •Typical combined AFC: ~16–20 at age 30, ~14–16 at 35, ~8–10 at 40, ~2–4 at 44.
- •AMH correlates with AFC; higher AMH = more follicles leaving the vault, thus better response to stimulation.
- •ACOG opposes AMH screening due to lack of prediction of monthly fecundability; Crawford argues that is the wrong metric.
- •Knowledge of low reserve in one’s 20s/30s can change life choices (egg freezing, timing, partner conversations, work/family plans).
- •AMH is relatively inexpensive and widely available; retest off hormonal contraception if low.
- 2:35:00 – 2:49:00
Egg Freezing: Timing, Process, and Success Math
Crawford outlines the egg freezing process, optimal age (around 32–33), modern survival rates, and the attrition from egg to live birth. She emphasizes that more eggs and younger age dramatically improve the chance of a future baby and potential for multiple children.
- •Modern vitrification yields ~90% egg survival upon thaw vs ~40% a decade ago.
- •Rough funnel: ~90% survive thaw, ~75% fertilize, ~50% reach blastocyst; then age-dependent percentage of those are chromosomally normal.
- •Each euploid embryo gives ~65% chance of live birth; cumulative ~88% after two, ~95% after three single-embryo transfers.
- •20 eggs at age 30 might yield ~4 euploid embryos—good odds for 1–2 children but not guaranteed.
- •Studies suggest intervening with egg freezing around 32–33 is ideal for the 'average' woman who isn’t ready to conceive.
- •Egg freezing and IVF use the same stimulation and retrieval procedure; only lab handling differs afterwards.
- 2:49:00 – 2:58:00
Sperm Freezing, Vasectomy, and Male Preconception Planning
They turn to male fertility planning: cheap, simple sperm freezing before vasectomy or later-life paternity, and practical guidelines around ejaculation intervals and semen analysis.
- •Sperm freezing involves infectious disease labs plus ejaculation after 2–3 days abstinence; it’s inexpensive and fast.
- •Men planning vasectomy should strongly consider banking sperm first; vasectomy reversals often fail or yield low counts requiring IVF.
- •Standard semen analyses and post-vasectomy tests are based on 48–72 hours abstinence; that window standardizes interpretation.
- •Daily intercourse during fertile windows does not harm sperm quality; it just distributes the same total output over more days.
- 2:58:00 – 3:16:00
IVF Stimulation, Retrieval, and Physical Experience for Patients
Crawford details ovarian stimulation protocols (FSH/LH injections), how follicles are monitored, and what patients feel. She explains how menopausal urine is used to purify LH-containing meds and how retrieval is performed under sedation.
- •Stimulation uses daily subcutaneous FSH and LH (e.g., purified from menopausal urine in products like Menopur) for ~10–14 days.
- •Suppression (e.g., birth control pills) before stimulation helps synchronize follicles so they grow together.
- •Patients often feel bloated and pressure as estrogen rises and follicles enlarge; mood is usually good in high-estrogen phases.
- •Egg retrieval is a transvaginal ultrasound-guided procedure under IV sedation (usually propofol plus optionally fentanyl) lasting ~20 minutes.
- •Patients must avoid intercourse from midway through stimulation until after the next period to prevent quintuplet-level pregnancies or severe OHSS.
- 3:16:00 – 3:30:00
Conventional IVF vs. ICSI and the INVOcell Technique
They compare conventional IVF (letting sperm fertilize eggs in a dish) with ICSI (injecting a selected sperm into each egg), and discuss INVOcell—a device that uses the vagina as a natural incubator. ICSI is now widely used to avoid total fertilization failure, especially with male factor issues or frozen eggs.
- •Conventional IVF: eggs are placed in a dish and bathed in processed semen; some proportion fertilizes naturally.
- •ICSI: embryologist selects a morphologically normal, motile sperm and injects it directly into the egg cytoplasm.
- •Egg freezing requires denuding (removal) of cumulus cells, so later fertilization must be by ICSI.
- •ICSI reduces risk of 0% fertilization; mild concerns about slightly increased birth defect risk have not held up strongly with modern protocols.
- •INVOcell allows fertilization and early embryo development inside a plastic device placed in the vagina, then one fresh embryo is transferred at day 5.
- •INVOcell can be cost-effective for specific patients (e.g., same-sex female couples, known tubal factor, some PCOS), but is poorly suited to unexplained infertility or male factor disease.
- 3:30:00 – 3:41:00
Embryo Banking, Three-Parent IVF, and Technology Limits
The conversation touches on embryo banking for family planning, three-parent IVF for mitochondrial disease, and the ethical and technical constraints of embryo research in the US. Crawford notes that mitochondrial transfer is clearly helpful for lethal mitochondrial diseases but has not reliably overcome age-related egg issues.
- •Embryo banking lets people in their late 30s or 40s accumulate multiple embryos now for first and future children.
- •Three-parent IVF (mitochondrial replacement) replaces diseased mitochondria with donor egg cytoplasm, proven valuable in severe mitochondrial disorders.
- •Using mitochondrial replacement purely for age-related infertility has not been consistently successful.
- •US policy and political views on embryos limit robust embryo research; many unused embryos sit in storage indefinitely.
- •Embryo donation is growing but ethically and logistically complex; there’s a 'Wild West' of embryo and gamete donation matching and quality.
- 3:41:00 – 3:55:00
IVF Babies, Autism, and Fresh vs. Frozen Transfer Outcomes
Huberman raises concerns about IVF and autism. Crawford clarifies that older IVF practices—fresh transfers into hyper-stimulated uterine environments and high-order multiples—likely drove some adverse outcomes, and that frozen transfers in more physiologic hormone settings have improved perinatal results. Advanced paternal age remains the strongest autism risk factor.
- •Fresh transfers after high-stimulation cycles create super-physiologic estrogen/progesterone and abnormal placental invasion patterns.
- •These environments were associated with preterm birth, small-for-gestational-age babies, and higher complication rates.
- •Modern practice favors freeze-all, then frozen embryo transfer in controlled, more natural hormonal conditions.
- •Infertility itself (regardless of IVF) raises birth defect risk by ~1% and developmental issues modestly, likely due to underlying biology.
- •Advanced paternal age (>50) shows the clearest association with increased autism and some dominant genetic disorders.
- 3:55:00 – 4:18:00
Nutrition and Supplements for Fertility and Hormone Health
They present an evidence-informed guide to diet and supplements for women and men trying to conceive or simply wanting optimal reproductive health. The focus is on reducing inflammation, supporting mitochondria, and ensuring key micronutrients like folate and vitamin D.
- •Plant-forward, anti-inflammatory patterns (Mediterranean-like) are consistently linked to better fecundability and IVF outcomes.
- •Fruits are beneficial despite fructose due to fiber and antioxidants; whole grains support gut health and hormone metabolism.
- •Dairy in whole-fat forms appears neutral or beneficial; ultra-processed low-fat dairy may be harmful.
- •Processed meats (bacon, hot dogs, deli meats) and high red-meat intake correlate with worse IVF embryo development.
- •Sugar and artificial sweeteners (sucralose, aspartame) are linked to higher inflammation and miscarriage; 'treats' are fine occasionally, day-to-day patterns matter.
- •Baseline supplements: prenatal with folic acid; vitamin D (at least 1000 IU/day); omega-3s (~1 g/day); CoQ10 (200 mg three times/day around IVF); myo-inositol (2 g/day) in PCOS; L-carnitine + vitamin C + CoQ10 for male factor.
- 4:18:00 – 4:30:00
PCOS, Inositol, and Metformin Trade-offs
They address PCOS as an ovulatory and metabolic condition, the benefits of myo-inositol, and side effects of metformin—especially its potential to lower testosterone in men using it for 'longevity.'
- •PCOS involves many follicles, chronic anovulation, and increased ovarian androgen production, leading to hirsutism, acne, and central adiposity.
- •Unopposed estrogen in PCOS raises endometrial cancer risk; pills or progestin therapy can be protective.
- •Myo-inositol improves insulin sensitivity and may decrease inflammation and ovarian androgen production in PCOS.
- •Metformin can lower testosterone levels; men using it for longevity or glucose control need to weigh potential hormonal costs.
- 4:30:00 – 4:46:00
Late Reproductive Planning, Embryo Numbers, and Realistic Expectations
Crawford walks through concrete numerical examples: how many eggs and embryos a 40-year-old might reasonably expect per cycle, why multiple cycles are often needed, and how genetic testing plus embryo banking can help older couples strategize family size.
- •At 40, each IVF cycle for an average-reserve woman might yield 4 embryos, of which ~1 may be chromosomally normal.
- •PGT-A allows that one normal embryo to be prioritized, giving ~65% chance of live birth vs ~20–30% per untested transfer.
- •Multiple cycles may be needed to bank enough embryos for multiple desired children, particularly starting at >37.
- •Batching cycles back-to-back after learning results is more efficient than spacing them out after months of failed transfers.
- •Embryo banking and counseling around realistic numbers reduces heartbreak and financial waste.
- 4:46:00 – 5:06:00
Perimenopause, Menopause, and Hormone Replacement Benefits
In the final section, they discuss early menopause, perimenopause symptoms, and the strong argument for timely hormone replacement. Crawford frames menopause as ovarian failure with far-reaching health consequences that can be mitigated by appropriately dosed estradiol plus progestin.
- •Menopause reflects ovarian failure: ovaries no longer respond to high FSH/LH and produce almost no estradiol/progesterone.
- •Women going through menopause earlier (often due to low reserve, chemo, untreated endometriosis, smoking, chronic illness) have shorter lifespans and higher cardiovascular, dementia, and osteoporosis risk.
- •Symptoms include hot flashes, night sweats, vaginal and vulvar atrophy, dyspareunia, mood changes, brain fog, and sleep disruption.
- •Initiating HRT near the onset of menopause—not a decade later—improves safety and benefit profiles; re-initiating estrogens after long hypoestrogenic intervals was what drove adverse outcomes in the Women’s Health Initiative.
- •Estradiol (via patch, pill, or vaginal prep) plus progestin (oral, cyclic, or via IUD) is standard; goal is lowest dose that relieves symptoms and protects brain, bone, and cardiovascular health.
- 5:06:00
Closing Reflections and Call for Better Women’s Health Education
Huberman and Crawford close by underscoring the importance of reproductive literacy for both women and men, across the lifespan. Crawford thanks the platform for elevating women’s health, and Huberman highlights the need to dispel myths so individuals can make informed, proactive choices.
- •Fertility intersects with overall health, longevity, psychological well-being, and life planning decisions.
- •Many myths—about egg freezing, birth control, and IVF—unnecessarily deter people from helpful options.
- •Crawford urges women with low ovarian reserve or early menopause risk to seek timely evaluation and consider HRT.
- •The conversation aims to normalize discussions about sexual and reproductive health and encourage data-driven decision-making.
